Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02777554 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
NCT02777554 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 144 participants.
The verdict
NCT02777554, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the relative bioavailability of apremilast once-daily formulation relative to a twice daily formulation when administered as multiple doses (Part 1), and when administered as a single dose under fasting and fed conditions (Part 2). Information on safety and tolerability will also be obtained.
Interventions
- DRUG Apremilast IR
- DRUG Apremilast XL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2016-08-17 |
| Est. Completion | 2016-11-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02777554
The ClinicalTrials.gov registry entry for NCT02777554 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apremilast IR is the first listed.
NCT02777554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02777554 about?
NCT02777554 is a clinical study titled "A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults". The purpose of this study is to evaluate the relative bioavailability of apremilast once-daily formulation relative to a twice daily formulation when administered as multiple doses (Part 1), and when administered as a single dose under fasting and fed conditions (Part 2). Information on safety and t...
What is the current status of trial NCT02777554?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2016-08-17. Estimated completion is 2016-11-22.
What interventions are being tested in trial NCT02777554?
The interventions under investigation include: Apremilast IR (DRUG), Apremilast XL (DRUG).
Who is sponsoring clinical trial NCT02777554?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.